Biogen BIIB initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult patients with primary membranous nephropathy (PMN). Top-line data readout ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Biogen acquired rights to Skyclarys in 2023 when it bought Reata Pharma for $7.3 billion. Analysts have previously suggested that the drug could make sales of more than $1 billion a year at its peak.

View Biogen Inc. BIIB stock quote prices, financial information, real-time forecasts, and company news from CNN.

Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...